Continuing education that matters: a successful, evidence-based course with minimal pharmaceutical funding.

Concerns about the influence of the pharmaceutical and medical device industries on continuing medical education (CME) have been voiced frequently over the past decade.1 Reliance on industry funding increases the potential for bias. Industry-supported CME often emphasizes conditions that can be treated with newer drugs or devices rather than those with the greatest public health impact, and risks becoming a tool for drug promotion.